Первичные лимфомы центральной нервной системы

Закрыть метаданные

На основании данных литературы освещены подходы к диагностике и лечению, сформулированы основные факторы неблагоприятного прогноза и критерии ответа на лечение редкой формы экстранодальных лимфом — первичных лимфом центральной нервной системы.

Ключевые слова:

первичные лимфомы центральной нервной системы

диффузная B-клеточная крупноклеточная лимфома центральной нервной системы

высокие дозы метотрексата

экстранодальная лимфома

Авторы:

Черкашина И.В.

Московский научно-исследовательский онкологический институт им. П.А. Герцена — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России

ORCID: 0000-0001-7096-4700

Вернюк М.А.

ORCID: 0000-0003-1497-2436

Хайруллина Л.С.

ORCID: 0000-0001-8520-0711

Феденко А.А.

ORCID: 0000-0003-4927-5585

Дата поступления:

01.06.2023

Дата принятия в печать:

09.06.2023

Список литературы:

Черкашина И.В., Вернюк М.А., Червонцева А.М., Гущина Е.Е., Хайруллина Л.С., Лунин В.В., Зейналова П.А., Феденко А.А. Лечение первичных лимфом центральной нервной системы. Онкогематология. 2021;16(2):10-20. https://doi.org/10.17650/1818-8346-2021-16-2-10-20
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2014—2018. Neuro Oncol. 2021;23(12 suppl 2):iii1-iii105. https://doi.org/10.1093/neuonc/noab200
Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414-1418. https://doi.org/10.1038/bjc.2011.357
Küker W, Nägele T, Korfel A, Heckl S, Thiel E, Bamberg M, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72(2):169-177. https://doi.org/10.1007/s11060-004-3390-7
Cheng G, Zhang J. Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients. Neurol Sci. 2019;40(3):535-542. https://doi.org/10.1007/s10072-018-3669-7
Nabavizadeh SA, Vossough A, Hajmomenian M, Assadsangabi R, Mohan S. Neuroimaging in central nervous system lymphoma. Hematol Oncol Clin North Am. 2016;30(4):799-821. https://doi.org/10.1016/j.hoc.2016.03.005
Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, Vossough A, O’Rourke DM, Judy KD, Poptani H, Melhem ER. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2011;32(3):507-514. https://doi.org/10.3174/ajnr.A2333
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. https://doi.org/10.1182/blood-2016-01-643569
Villa D, Tan KL, Steidl C, Ben-Neriah S, Al Moosawi M, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Scott DW, et al. Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Adv. 2019;3(23):3953-3961. https://doi.org/10.1182/bloodadvances.2019000989
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266-272. https://doi.org/10.1200/JCO.2003.09.139
Jang JE, Kim YR, Kim SJ, Cho H, Chung H, Lee JY, Park H, Kim Y, Cheong JW, Min YH, et al. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. Eur J Cancer. 2016;57:127-135. https://doi.org/10.1016/j.ejca.2016.01.016
Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 2005;31(1):100-105. https://doi.org/10.1016/j.ejso.2004.10.002
Milgrom SA, Yahalom J. The role of radiation therapy in the management of primary central nervous system lymphoma. Leuk Lymphoma. 2015;56(5):1197-1204. https://doi.org/10.3109/10428194.2014.961014
Koh HK, Kim IH, Kim TM, Lim DH, Oh D, Cho JH, Kim WC, Kim JH, Chung WK, Jeong BK, et al. Role of radiation therapy in primary central nervous system lymphoma: KROG 14—20 Collaborative Study of Brain and Lymphoma Committee. J Neurooncol. 2017;135(3):629-638. https://doi.org/10.1007/s11060-017-2616-4
Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061-3068. https://doi.org/10.1200/JCO.2012.46.9957
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, et al.; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512-1520. https://doi.org/10.1016/S0140-6736(09)61416-1
Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466-468. https://doi.org/10.1182/blood-2002-06-1636
Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730-4735. https://doi.org/10.1200/JCO.2007.12.5062
Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, Ninkovic S, Eyre TA, Cummin T, Smith J, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system — an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189(5):879-887. https://doi.org/10.1111/bjh.16451
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403-1410. https://doi.org/10.1182/blood-2014-10-604561
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251-e259. https://doi.org/10.1016/S2352-3026(15)00074-5
Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol. 2016;34(14);1620-1625. https://doi.org/10.1200/JCO.2015.64.8634
Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9-17. https://doi.org/10.1016/0360-3016(92)90538-S
Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021;7(7):993-1003. https://doi.org/10.1001/jamaoncol.2021.1074
Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol. 2019;184(3):348-363. https://doi.org/10.1111/bjh.15661
Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol. 2012;14(1):101-108. https://doi.org/10.1093/neuonc/nor186
Lee TH, Lee JH, Chang JH, Ye SJ, Kim TM, Park CK, Kim IH, Kim BH, Wee CW. Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. Radiat Oncol J. 2020;38(1):35-43. https://doi.org/10.3857/roj.2020.00052
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971-3979. https://doi.org/10.1200/JCO.2013.50.4910
Herrlinger U, Schäfer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, et al. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol. 2017;143(9):1815-1821. https://doi.org/10.1007/s00432-017-2423-5
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, et al.; International Extranodal Lymphoma Study Group (IELSG). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510-e523. https://doi.org/10.1016/S2352-3026(17)30174-6
Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, et al.; Intergroupe GOELAMS-ANOCEF and the LOC Network for CNS Lymphoma. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019;37(10):823-833. https://doi.org/10.1200/JCO.18.00306
Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620-1625. https://doi.org/10.1200/JCO.2015.64.8634
Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 2015;100(4):534-540. https://doi.org/10.3324/haematol.2014.108472
Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846-852. https://doi.org/10.1038/leu.2016.334
Ambady P, Fu R, Szidonya L, Peereboom DM, Doolittle ND, Neuwelt EA. Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma. J Neurooncol. 2020;147(1):171-176. https://doi.org/10.1007/s11060-020-03411-0
Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043. https://doi.org/10.1200/JCO.2005.13.524
Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004;10(17):5643-5646. https://doi.org/10.1158/1078-0432.CCR-04-0159
Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol. 2014;117(1):161-165. https://doi.org/10.1007/s11060-014-1370-0
Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquières H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica. 2012;97(11):1751-1756. https://doi.org/10.3324/haematol.2011.060434
Reni M, Mazza E, Foppoli M, Ferreri AJ. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate. Cancer Lett. 2007;258(2):165-170. https://doi.org/10.1016/j.canlet.2007.10.009
Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A.; German Primary Central Nervous System Lymphoma Study Group. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80(2):159-165. https://doi.org/10.1007/s11060-006-9165-6
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833-843.e5. https://doi.org/10.1016/j.ccell.2017.04.012
Schaff LR, Ambady P, Doolittle ND, Grommes C. Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies. Ann Lymphoma. 2021;5:8. https://doi.org/10.21037/aol-20-47
Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595-1607. https://doi.org/10.1182/bloodadvances.2017014845
Nayak L, Iwamoto FM, Lacasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071-3073. https://doi.org/10.1182/blood-2017-01-764209

Закрыть метаданные